Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Bussel

Showing results (161-170 of 262) with videos related to

Pageof 27
Sort By:
The Journal of Experimental Medicine|June 15, 2007
CD40 ligand and MHC class II expression are essential for human peripheral B cell toleranceMaxime Hervé, Isabelle Isnardi, Yen-shing Ng, et al.
Haematologica|January 28, 2014
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-upWaleed Ghanima, Julia Turbiner Geyer, Christina S Lee, et al.
British Journal of Haematology|April 3, 2004
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraNichola Cooper, Roberto Stasi, Susanna Cunningham-Rundles, et al.
British Journal of Haematology|August 30, 2021
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND studyOliver Meyer, Raymond S M Wong, Abderrahim Khelif, et al.
Pediatric Blood & Cancer|August 3, 2024
Familial autoimmunity and risk of developing immune thrombocytopenia and Evans syndromeMichell M Lozano Chinga, James B Bussel, Mark N Fluchel, et al.
Blood|March 6, 2002
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?Nichola Cooper, B Michael R Woloski, Erin M Fodero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 7, 2017
Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight casesHamilton C Tsang, James B Bussel, Susan Mathew, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Blood|October 19, 2017
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND studyRaymond S M Wong, Mansoor N Saleh, Abderrahim Khelif, et al.
Haematologica|August 13, 2016
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopeniaHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Pageof 27

Showing results (161-170 of 262) with videos related to

Sort By:
Pageof 27
The Journal of Experimental Medicine|June 15, 2007
CD40 ligand and MHC class II expression are essential for human peripheral B cell toleranceMaxime Hervé, Isabelle Isnardi, Yen-shing Ng, et al.
Haematologica|January 28, 2014
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-upWaleed Ghanima, Julia Turbiner Geyer, Christina S Lee, et al.
British Journal of Haematology|April 3, 2004
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraNichola Cooper, Roberto Stasi, Susanna Cunningham-Rundles, et al.
British Journal of Haematology|August 30, 2021
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND studyOliver Meyer, Raymond S M Wong, Abderrahim Khelif, et al.
Pediatric Blood & Cancer|August 3, 2024
Familial autoimmunity and risk of developing immune thrombocytopenia and Evans syndromeMichell M Lozano Chinga, James B Bussel, Mark N Fluchel, et al.
Blood|March 6, 2002
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?Nichola Cooper, B Michael R Woloski, Erin M Fodero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 7, 2017
Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight casesHamilton C Tsang, James B Bussel, Susan Mathew, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Blood|October 19, 2017
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND studyRaymond S M Wong, Mansoor N Saleh, Abderrahim Khelif, et al.
Haematologica|August 13, 2016
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopeniaHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Pageof 27